Eli Lilly
Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly
Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High
Lilly continues full-court press against breast cancer with women’s March Madness event sponsorships
Eli Lilly, Woman, Madness, Malignant neoplasm of breast, Event, Awareness, Basketball game
Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia
Solbinsiran, siRNA, mixed dyslipidemia, Eli Lilly, PROLONG-ANG3, apolipoprotein B, LDL-C, triglycerides
BioSpace Presents the World Atlas of GLP-1s
Eli Lilly, Wegovy, India, China, BioSpace, World, Cervical Atlas, GLP-1s, Nordisk, Glucagon-Like Peptide 1, Brazil, India
In an unusual move, Lilly seeks pitches from US states for slice of $27B buildout
Eli Lilly, Investments, United States, Lilly ‘s
Eli Lilly Partners with Magnet Biomedicine in $1.25B Molecular Glue Deal
Eli Lilly, Magnet Biomedicine, molecular glue, drug discovery, oncology, collaboration
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
Eli Lilly makes Zepbound vials cheaper for self-paying patients
self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg
Lilly lowers price of Zepbound vials, launches new doses
Eli Lilly, Dosage, Prices, Affordability, Obesity
Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships
Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations